The Jerusalem PostGorillas at Ramat Gan Safari form 'living ladder' to reach food, TAU study findsDaily MaverickWELLNESS: Nightmares explained, and why we have them at all한겨레실손 1·2세대, ‘5세대 갈아타기’ 10%대 그쳐…“기존 혜택 더 중요”ZDF heuteAktuelle Pressemitteilungen des ZDFCNN TürkFRANSA -TÜRKİYE MAÇ SONUCU | Fransa - Türkiye Maç Özeti: Milli maç kaç kaç bitti? A Milli Takım A Ligi'nden elendi mi?SRF NewsKrieg in der Ukraine – Prinz Harry überrascht mit Ukraine-Besuchالنهارصباح النهار: مهمّة مزدوجة لوالتز وصيغة بديلة من "اليونيفيل"... "حرب الرادارات"South China Morning PostBid to marry off pregnant girl, 12, in Malaysia leads to man’s arrestHet Laatste NieuwsEchte herfstdag met buien en opklaringen en ook hevige windMyJoyOnlineGhana records GHS209.7m in cybersecurity losses in nine monthsESPN🏈 Connelly sizes up CFB's best races down the homestretchHabertürk"Her anını kalbime sakladım"
The Daily Newsstand · Free, Always
Monday, November 16, 2026

Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback

Translate

Shares in Hong Kong-listed Akeso plunged as much as 31.8 per cent on Monday morning after the US Food and Drug Administration (FDA) rejected its cancer drug application, raising investor worries over the company’s near-term commercial outlook. Ivonescimab, one of the most closely

Read the full article on South China Morning Post →

KioskNews shows the publisher’s own headline, image, and summary — the full article always lives on their site, not ours.